Under AAAResearchReports.com Microscope: Zoetis Inc., Teva Pharma Industries Ltd, Covidien PLC, and Valeant Pharma Intl. Inc.

Editor Note: For more information about this release, please scroll to bottom

LONDON, September 27, 2013 /PRNewswire/ --

The U.S. equity market posted gains on Thursday, September 26, 2013. The Dow Jones Industrial Average ended the day at 15,328.30, up 0.36%; the S&P 500 closed at 1,698.67, up 0.35%; and the NASDAQ Composite finished at 3,787.43, up 0.70%. Shares in the healthcare sector ended on a mixed note as the broader market edged higher. The major movers in the sector included Zoetis Inc. (NYSE: ZTS), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Covidien Plc. (NYSE: COV), and Valeant Pharmaceuticals International Inc. (NYSE: VRX). AAAResearchReports.com has released full comprehensive research on ZTS, TEVA, COV, and VRX. These free technical analyses can be downloaded by signing up at:


Shares in Zoetis Inc. rose sharply on Thursday, tracking gains in the broader market. The company's shares finished the day 1.67% higher at $31.58 after fluctuating between $31.20 and $31.64 during the trading session. A total of 2.29 million shares were traded, which is below the daily average volume of 6.46 million. The company's shares have gained 5.97% in the previous one month, outperforming the S&P 500 which has advanced 2.53% during the same period. Further, Zoetis Inc.'s stock is trading above its 50-day moving average of $30.58. A free technical analysis on ZTS available by signing up at:


On Thursday, Teva Pharmaceutical Industries Ltd's shares oscillated between $37.88 and $38.37 before closing the day at $37.93, which is 0.60% lower than the previous day's closing price of $38.16. A total of 1.86 million shares were traded, which is below the daily average volume of 3.40 million. The company's shares have lost 0.21% in the previous three trading sessions, underperforming the S&P 500 which has lost 0.19% during the same period. Moreover, Teva Pharmaceutical Industries Ltd's stock is trading below its 50-day and 200-day moving averages of $39.04 and $38.85, respectively. Register today and access free research on TEVA at:


Covidien PLC's stock edged lower on Thursday, even as the broader market posted gains. The company's shares fluctuated between $60.67 and $61.45 before finishing the day 0.25% lower at $60.97. A total of 1.82 million shares were traded, which is below the daily average volume of 2.39 million. Despite Thursday's pullback, the company's shares have gained 7.42% in the previous three months, compared to a gain of 5.95% in the S&P 500 during the same period. Furthermore, Covidien PLC's stock is trading above its 200-day moving average of $58.72. The free report on COV can be downloaded by signing up now at:


Shares in Valeant Pharmaceuticals International Inc. rose 0.93% on Thursday, reversing most of the losses from the previous trading session. The company's shares vacillated between $102.30 and $103.53 before ending the day at $103.29. A total of 0.45 million shares were traded, which is below the daily average volume of 1.27 million. The company's shares have gained 3.70% in the last one month and 21.59% in the previous three months, outperforming the S&P 500 which has advanced 2.53% and 5.95% during the respective periods. Moreover, Valeant Pharmaceuticals International Inc.'s stock is trading above its 50-day and 200-day moving averages of $98.51 and $79.46, respectively. A free report on VRX can be accessed by registering at:




  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE AAA Research Reports

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.